Skip to main content

Table 1 Baseline Characteristics and Concomitant Medications

From: Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial

CharacteristicTreatment groupP value
GXST (n = 143)Placebo (n = 144)
Demographics   
 Gender (M/F)(73/70)(82/62)0.16
 Age (years)56.6 ± 8.155.3 ± 8.30.15
 Height (cm)166.6 ± 7.7167.5 ± 7.70.31
 Weight (kg)68.9 ± 10.268.9 ± 9.81.00
 HR (beats/min)71.2 ± 9.370.7 ± 9.30.64
 SBP (mmHg)128.8 ± 9.7129.0 ± 9.20.90
 DBP (mmHg)80.9 ± 7.280.1 ± 7.70.41
Baseline characteristics
 Angina frequency (no. of events per week)9.4 ± 3.29.0 ± 3.00.32
 NTG consumption (no. of pills per week)5.8 ± 3.55.5 ± 3.00.49
 SAQ score
  Physical limitations
  Angina stability
  Angina frequency
  Treatment satisfaction
  QOL
46.8 ± 10.6
51.8 ± 11.1
51.8 ± 8.7
36.9 ± 20.0
46.5 ± 18.2
44.4 ± 19.5
48.2 ± 12.0
54.1 ± 12.0
51.0 ± 9.1
43.6 ± 21.1
47.5 ± 19.2
45.0 ± 20.4
0.28
0.08
0.42
0.09
0.64
0.81
 ETT Time to onset of chest pain (s)430.24 ± 177.2456.42 ± 188.720.71
 Time to 1 mm ST-depression (s)235.95 ± 153.11237.69 ± 174.340.96
Concomitant medication
 β-blocker10 (7.0%)15 (10.4)0.15
 ACEI3 (2.1%)0 (0.0%)0.06
 ARB10 (7.0%)8 (5.6%)0.31
 CCB10 (7.0%)9 (6.3%)0.40
 Stains126 (88.1%)125 (86.8%)0.38
 Anti-platelet agents138 (96.5%)140 (97.2%)0.41
  1. Each value represents the mean ± SD or the number (%)
  2. GXST, Guanxinshutong capsule; ACEI, angiotensin I converting enzyme inhibitors; ARB, angiotensin II receptor blockers; CCB, calcium channel blockers, ETT, exercise treadmill test; QOL, quality of life; SAQ, Seatntle Agina Questionnaire; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate